Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field. Backed by their common shareholder, Keensight Capital, one …
We are thrilled to announce that Biovian will be exhibiting at the upcoming Oncolytic Virotherapy Summit, scheduled to take place from December 12-14 in the vibrant city of Boston, MA. As part of this summit, …
We are delighted to announce that Magnus Gustafsson, CBO at Biovian, will be presenting and participating in a panel discussion at the Global Bioprocessing Summit in Berlin! The Global Bioprocessing Summit, taking place on November …
Junior Chamber International (JCI) Turku has recognized Biovian as the Turku Developer 2023. We are delighted and honored to announce that Biovian has received the Turku Developer 2023 award by JCI Turku, Finland on Friday, …
We invite you to explore the recent article “Next Level Biopharmaceuticals” featured in the Business Focus Magazine’s latest issue. Business Focus Magazine interviewed Biovian’s CEO and co-founder Antti Nieminen about Biovian’s growth story and position …
Biovian, a biopharmaceutical CDMO providing One-Stop-Shop GMP services to a global client base, is delighted to announce the appointment of Jayme Tortorici, based in San Diego, CA, as its new Business Development Director. Jayme Tortorici …
The article discusses the reasons behind the growing need for viral vectors and how Biovian, as a CDMO has taken actions to solve the manufacturing bottleneck. Antti Nieminen, CEO of Biovian: “The majority of Biovian’s customers …
Biovian’s client satisfaction survey was conducted in November using Net Promoter Score (NPS) survey. The score of 67 puts Biovian into the category “Excellent” based on the creators of NPS, Bain & Co. Flexibility, good …
Biovian received a new automated filling line right before Christmas in 2020 from Optima packaging group. This article describes the project from the planning phase until the assembly of the filling line. The project is …
Biovian and Lokon Pharma are featured in Biopharma Dealmakers September issue. The article “Manufacturing the next generation of cancer immunotherapeutics”, describes the history and currents state of Lokon Pharma’s proprietary LOAd technology. This immunostimulatory gene …
